NOTE: This dataset has been retired and marked as historical-only.

Only Chicago residents are included based on the home ZIP Code as provided by the medical provider. If a ZIP was missing or was not valid, it is displayed as "Unknown".

Cases with a positive molecular (PCR) or antigen test are included in this dataset. Cases are counted based on the week the test specimen was collected. For privacy reasons, until a ZIP Code reaches five cumulative cases, both the weekly and cumulative case counts will be blank. Therefore, summing the “Cases - Weekly” column is not a reliable way to determine case totals. Deaths are those that have occurred among cases based on the week of death.

For tests, each test is counted once, based on the week the test specimen was collected. Tests performed prior to 3/1/2020 are not included. Test counts include multiple tests for the same person (a change made on 10/29/2020). PCR and antigen tests reported to Chicago Department of Public Health (CDPH) through electronic lab reporting are included. Electronic lab reporting has taken time to onboard and testing availability has shifted over time, so these counts are likely an underestimate of community infection.

The “Percent Tested Positive” columns are calculated by dividing the number of positive tests by the number of total tests . Because of the data limitations for the Tests columns, such as persons being tested multiple times as a requirement for employment, these percentages may vary in either direction from the actual disease prevalence in the ZIP Code.

All data are provisional and subject to change. Information is updated as additional details are received.

To compare ZIP Codes to Chicago Community Areas, please see http://data.cmap.illinois.gov/opendata/uploads/CKAN/NONCENSUS/ADMINISTRATIVE_POLITICAL_BOUNDARIES/CCAzip.pdf. Both ZIP Codes and Community Areas are also geographic datasets on this data portal.

Data Source: Illinois National Electronic Disease Surveillance System, Cook County Medical Examiner’s Office, Illinois Vital Records, American Community Survey (2018)

NOTE: This dataset has been retired and marked as historical-only. This dataset is a companion to the COVID-19 Daily Cases and Deaths dataset (https://data.cityofchicago.org/d/naz8-j4nc). The major difference in this dataset is that the case, death, and hospitalization corresponding rates per 100,000 population are not those for the single date indicated. They are rolling averages for the seven-day period ending on that date. This rolling average is used to account for fluctuations that may occur in the data, such as fewer cases being reported on weekends, and small numbers. The intent is to give a more representative view of the ongoing COVID-19 experience, less affected by what is essentially noise in the data. All rates are per 100,000 population in the indicated group, or Chicago, as a whole, for “Total” columns. Only Chicago residents are included based on the home address as provided by the medical provider. Cases with a positive molecular (PCR) or antigen test are included in this dataset. Cases are counted based on the date the test specimen was collected. Deaths among cases are aggregated by day of death. Hospitalizations are reported by date of first hospital admission. Demographic data are based on what is reported by medical providers or collected by CDPH during follow-up investigation. Denominators are from the U.S. Census Bureau American Community Survey 1-year estimate for 2018 and can be seen in the Citywide, 2018 row of the Chicago Population Counts dataset (https://data.cityofchicago.org/d/85cm-7uqa). All data are provisional and subject to change. Information is updated as additional details are received and it is, in fact, very common for recent dates to be incomplete and to be updated as time goes on. At any given time, this dataset reflects cases and deaths currently known to CDPH. Numbers in this dataset may differ from other public sources due to definitions of COVID-19-related cases and deaths, sources used, how cases and deaths are associated to a specific date, and similar factors. Data Source: Illinois National Electronic Disease Surveillance System, Cook County Medical Examiner’s Office, U.S. Census Bureau American Community Survey

NOTE: This dataset has been retired and marked as historical-only.

Weekly rates of COVID-19 cases, hospitalizations, and deaths among people living in Chicago by vaccination status and age.

Rates for fully vaccinated and unvaccinated begin the week ending April 3, 2021 when COVID-19 vaccines became widely available in Chicago. Rates for boosted begin the week ending October 23, 2021 after booster shots were recommended by the Centers for Disease Control and Prevention (CDC) for adults 65+ years old and adults in certain populations and high risk occupational and institutional settings who received Pfizer or Moderna for their primary series or anyone who received the Johnson & Johnson vaccine.

Chicago residency is based on home address, as reported in the Illinois Comprehensive Automated Immunization Registry Exchange (I-CARE) and Illinois National Electronic Disease Surveillance System (I-NEDSS).

Outcomes: • Cases: People with a positive molecular (PCR) or antigen COVID-19 test result from an FDA-authorized COVID-19 test that was reported into I-NEDSS. A person can become re-infected with SARS-CoV-2 over time and so may be counted more than once in this dataset. Cases are counted by week the test specimen was collected. • Hospitalizations: COVID-19 cases who are hospitalized due to a documented COVID-19 related illness or who are admitted for any reason within 14 days of a positive SARS-CoV-2 test. Hospitalizations are counted by week of hospital admission. • Deaths: COVID-19 cases who died from COVID-19-related health complications as determined by vital records or a public health investigation. Deaths are counted by week of death.

Vaccination status: • Fully vaccinated: Completion of primary series of a U.S. Food and Drug Administration (FDA)-authorized or approved COVID-19 vaccine at least 14 days prior to a positive test (with no other positive tests in the previous 45 days). • Boosted: Fully vaccinated with an additional or booster dose of any FDA-authorized or approved COVID-19 vaccine received at least 14 days prior to a positive test (with no other positive tests in the previous 45 days). • Unvaccinated: No evidence of having received a dose of an FDA-authorized or approved vaccine prior to a positive test.

CLARIFYING NOTE: Those who started but did not complete all recommended doses of an FDA-authorized or approved vaccine prior to a positive test (i.e., partially vaccinated) are excluded from this dataset.

Incidence rates for fully vaccinated but not boosted people (Vaccinated columns) are calculated as total fully vaccinated but not boosted with outcome divided by cumulative fully vaccinated but not boosted at the end of each week. Incidence rates for boosted (Boosted columns) are calculated as total boosted with outcome divided by cumulative boosted at the end of each week. Incidence rates for unvaccinated (Unvaccinated columns) are calculated as total unvaccinated with outcome divided by total population minus cumulative boosted, fully, and partially vaccinated at the end of each week. All rates are multiplied by 100,000.

Incidence rate ratios (IRRs) are calculated by dividing the weekly incidence rates among unvaccinated people by those among fully vaccinated but not boosted and boosted people.

Overall age-adjusted incidence rates and IRRs are standardized using the 2000 U.S. Census standard population.

Population totals are from U.S. Census Bureau American Community Survey 1-year estimates for 2019.

All data are provisional and subject to change. Information is updated as additional details are received and it is, in fact, very common for recent dates to be incomplete and to be updated as time goes on. This dataset reflects data known to CDPH at the time when the dataset is updated each week.

Numbers in this dataset may differ from other public sources due to when data are reported and how City of Chicago boundaries are defined.

For all datasets related to COVID-19, see https://data.cityofchic

NOTE: This dataset is no longer being updated but is being kept for historical reference. For current data on respiratory illness visits and respiratory laboratory testing data please see Influenza, COVID-19, RSV, and Other Respiratory Virus Laboratory Surveillance and Inpatient, Emergency Department, and Outpatient Visits for Respiratory Illnesses.

In Illinois, influenza associated Intensive Care Unit (ICU) hospitalizations are reportable as soon as possible, but within 24 hours. Influenza associated ICU hospitalizations are defined as individuals hospitalized in an ICU with a positive laboratory test for influenza A or B, including specimens identified as influenza A/H3N2, A/H1N1pdm09, and specimens not subtyped (e.g., influenza positive cases by PCR or any rapid test such as EIA).

This dataset represents weekly aggregated information for influenza-associated ICU hospitalizations among Chicago residents, which is a reportable condition in Illinois.

Information includes demographics, influenza laboratory results, vaccination status, and death status.

Column names containing "REPORTED" indicate the number of cases for which the indicated data element was reported. This, rather than the total number of cases, is used to calculate the corresponding percentage.

All data are provisional and subject to change. Information is updated as additional details are received. At any given time, this dataset reflects data currently known to CDPH. Numbers in this dataset may differ from other public sources.

The global Electric Air Supply Grinding Mask market is poised for significant expansion, projected to reach an estimated $850 million by 2025, with a robust Compound Annual Growth Rate (CAGR) of 9.5% through 2033. This growth is primarily fueled by the increasing emphasis on worker safety and stringent regulatory mandates across industries such as construction and mining. The inherent risks associated with grinding operations, including exposure to harmful dust, fumes, and particulate matter, necessitate advanced respiratory protection. Consequently, demand for electric air-supplied grinding masks, offering superior protection and comfort compared to traditional respirators, is escalating. Technological advancements are also playing a crucial role, with manufacturers introducing lighter, more ergonomic designs, improved filtration systems, and enhanced battery life, further driving market adoption. The expanding industrial infrastructure, particularly in emerging economies, and the growing awareness among employers regarding the long-term health benefits of investing in high-quality personal protective equipment (PPE) are also significant contributors to this positive market trajectory. The market is segmented by application, with Construction Site applications dominating, followed by Mining and Others. The Full Face mask type is expected to hold a larger market share due to its comprehensive facial protection. Geographically, the Asia Pacific region is emerging as a dominant force, driven by rapid industrialization and increasing investments in infrastructure and manufacturing in countries like China and India. North America and Europe also represent substantial markets, supported by well-established industrial bases and rigorous safety standards. Key players like 3M, Illinois Tool Works, and Honeywell International are at the forefront of innovation, continually introducing advanced solutions to meet evolving industry demands. While the market exhibits strong growth potential, potential restraints include the relatively higher initial cost of electric air-supplied systems compared to disposable respirators, and the need for proper maintenance and battery management. However, the long-term cost savings through reduced health issues and increased worker productivity are expected to outweigh these initial considerations.